Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

Acta Biomaterialia

Volumn 10, Issue 7, 2014, Pages 2965-2975

  Dakwar, George R ^a   Zagato, Elisa ^a   Delanghe, Joris ^b   Hobel, Sabrina ^c   Aigner, Achim ^c   Denys, Hannelore ^b   Braeckmans, Kevin ^a   Ceelen, Wim ^b   De Smedt, Stefaan C ^a   Remaut, Katrien ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Aggregation; Drug delivery; Intraperitoneal administration; Peritoneal carcinomatosis; Release

Indexed keywords

AGGLOMERATION; BODY FLUIDS; CONTROLLED DRUG DELIVERY; FLUORESCENCE SPECTROSCOPY; MICELLES; NANOPARTICLES; PARTICLE SIZE; PATIENT MONITORING; POLYETHYLENE GLYCOLS; SPECTROSCOPIC ANALYSIS; TARGETED DRUG DELIVERY;

COLLOIDAL STABILITY; DELIVERY VEHICLE; DRUG-DELIVERY SYSTEMS; INTRAPERITONEAL; INTRAPERITONEAL ADMINISTRATION; NANO SIZED; PERITONEAL CARCINOMATOSIS; PERITONEAL FLUID; RELEASE; SMALL INTERFERING RNA;

LIPOSOMES;

LIPOSOME; MACROGOL; NANOPARTICLE; POLYSTYRENE; SMALL INTERFERING RNA; COLLOID;

ANIMAL EXPERIMENT; ARTICLE; ASCITES FLUID; BLOOD SAMPLING; CARCINOMATOSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FLUORESCENCE; FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PERITONEAL CARCINOMATOSIS; PERITONEAL DISEASE; PERITONEAL FLUID; PREMATURITY; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; COLLOID; INFUSION;

MUS;

ANIMALS; ASCITIC FLUID; COLLOIDS; DRUG DELIVERY SYSTEMS; INFUSIONS, PARENTERAL; LIPOSOMES; MICE; NANOPARTICLES;

EID: 84901813832     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.03.012     Document Type: Article

References (59)

1. J. Hunn, and G.C. Rodriguez Ovarian cancer: etiology, risk factors, and epidemiology Clin Obstet Gynecol 55 2012 3 23
2. Y.L.B. Klaver, V.E.P.P. Lemmens, S.W. Nienhuijs, M.D.P. Luyer, and I.H.J.T. de Hingh Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options World J Gastroenterol 18 2012 5489 5494
3. A. Poveda, R. Salazar, J.M. del Campo, C. Mendiola, J. Cassinello, and B. Ojeda et al. Update in the management of ovarian and cervical carcinoma Clin Transl Oncol 9 2007 443 451
4. J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, and R. Wong et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
5. R. Porschen, H.T. Arkenau, S. Kubicka, R. Greil, T. Seufferlein, and W. Freier et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group J Clin Oncol 25 2007 4217 4223
6. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. OToole, S.D. Williams, and J.A. Young et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955
7. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J Clin Oncol 21 2003 3194 3200
8. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 2011 183 203
9. M.J. Koppe, O.C. Boerman, W.J.G. Oyen, and R.P. Bleichrodt Peritoneal carcinomatosis of colorectal origin - incidence and current treatment strategies Ann Surg 243 2006 212 222
10. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
11. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
12. O. Glehen, F. Kwiatkowski, P.H. Sugarbaker, D. Elias, E.A. Levine, and M. De Simone et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study J Clin Oncol 22 2004 3284 3292
13. R.L. Dedrick, C.E. Myers, P.M. Bungay, and V.T. Devita Pharmacokinetic rationale for peritoneal drug administration in treatment of ovarian cancer Cancer Treat Rep 62 1978 1 11
14. D. Hompes, A. D'Hoore, E. Van Cutsem, S. Fieuws, W. Ceelen, and M. Peeters et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study Ann Surg Oncol 19 2012 2186 2194
15. P.H. Sugarbaker Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract 2012 10.1155/2012/309417
16. W.P. Ceelen, and M.F. Flessner Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence Nat Rev Clin Oncol 7 2010 108 115
17. Y.L.B. Klaver, T. Hendriks, R.M.L.M. Lomme, H.J.T. Rutten, R.P. Bleichrodt, and I.H.J.T. de Hingh Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study Ann Surg Oncol 19 2012 S475 S482
18. P. Zahedi, J. Stewart, R. De Souza, M. Piquette-Miller, and C. Allen An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels J Control Release 158 2012 379 385
19. Goldberg MS. siRNA delivery for the treatment of ovarian cancer, Methods [in press].
20. M. Creixell, and N.A. Peppas Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance Nano Today 7 2012 367 379
21. G. Bajaj, and Y. Yeo Drug delivery systems for intraperitoneal therapy Pharm Res-Dordr 27 2010 735 738
22. Z. Lu, J. Wang, M.G. Wientjes, and J.L.S. Au Intraperitoneal therapy for peritoneal cancer Future Oncol 6 2010 1625 1641
23. J. Tomasina, S. Lheureux, P. Gauduchon, S. Rault, and A. Malzert-Freon Nanocarriers for the targeted treatment of ovarian cancers Biomaterials 34 2013 1073 1101
24. S. Hallaj-Nezhadi, C.R. Dass, and F. Lotfipour Intraperitoneal delivery of nanoparticles for cancer gene therapy Future Oncol 9 2013 59 68
25. H. Cho, T.C. Lai, and G.S. Kwon Poly(ethylene glycol)-block-poly(epsilon- caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer J Control Release 166 2013 1 9
26. J. Fujiyama, Y. Nakase, K. Osaki, C. Sakakura, H. Yamagishi, and A. Hagiwara Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application J Control Release 89 2003 397 408
27. Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, and J.L.S. Au Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer J Pharmacol Exp Ther 327 2008 673 682
28. W.K. Bae, M.S. Park, J.H. Lee, J.E. Hwang, H.J. Shim, and S.H. Cho et al. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer Biomaterials 34 2013 1433 1441
29. G. Bajaj, M.R. Kim, S.I. Mohammed, and Y. Yeo Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors J Control Release 158 2012 386 392
30. J. Yu, H.J. Lee, K. Hur, M.K. Kwak, T.S. Han, and W.H. Kim et al. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model Invest New Drugs 30 2012 1 7
31. C.D. Walkey, and W.C.W. Chan Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment Chem Soc Rev 41 2012 2780 2799
32. Z.H. Liu, Y.P. Jiao, T. Wang, Y.M. Zhang, and W. Xue Interactions between solubilized polymer molecules and blood components J Control Release 160 2012 14 24
33. D. Zhong, Y.P. Jiao, Y. Zhang, W. Zhang, N. Li, and Q.H. Zuo et al. Effects of the gene carrier polyethyleneimines on structure and function of blood components Biomaterials 34 2013 294 305
34. V. Mirshafiee, M. Mahmoudi, K.Y. Lou, J.J. Cheng, and M.L. Kraft Protein corona significantly reduces active targeting yield Chem Commun 49 2013 2557 2559
35. A. Salvati, A.S. Pitek, M.P. Monopoli, K. Prapainop, F.B. Bombelli, and D.R. Hristov et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface Nat Nanotechnol 8 2013 137 143
36. K. Braeckmans, K. Buyens, W. Bouquet, C. Vervaet, P. Joye, and F. De Vos et al. Sizing nanomatter in biological fluids by fluorescence single particle tracking Nano Lett 10 2010 4435 4442
37. M.A. Dobrovolskaia, A.K. Patri, J.W. Zheng, J.D. Clogston, N. Ayub, and P. Aggarwal et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles Nanomedicine 5 2009 106 117
38. K. Buyens, B. Lucas, K. Raemdonck, K. Braeckmans, J. Vercammen, and J. Hendrix et al. A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum J Control Release 126 2008 67 76
39. J.L. Orsonneau, P. Douet, C. Massoubre, P. Lustenberger, and S. Bernard An improved pyrogallol red molybdate method for determining total urinary protein Clin Chem 35 1989 2233 2236
40. X. Bossuyt, B. Lissoir, G. Marien, D. Maisin, J. Vunckx, and N. Blanckaert et al. Automated serum protein electrophoresis by Capillarys (R) Clin Chem Lab Med 41 2003 704 710
41. C. Gay-Bellile, D. Bengoufa, P. Houze, D. Le Carrer, M. Benlakehal, and B. Bousquet et al. Automated multicapillary electrophoresis for analysis of human serum proteins Clin Chem 49 2003 1909 1915
42. L.T. Sniegoski, and J.R. Moody Determination of serum and blood densities Anal Chem 51 1979 1577 1578
43. N. Symens, R. Walczak, J. Demeester, I. Mattaj, S.C. De Smedt, and K. Remaut Nuclear inclusion of nontargeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles Mol Pharm 8 2011 1757 1766
44. B.K. Zebrowski, W.B. Liu, K. Ramirez, Y. Akagi, G.B. Mills, and L.M. Ellis Markedly elevated levels of vascular endothelial growth factor in malignant ascites Ann Surg Oncol 6 1999 373 378
45. B. Naeye, H. Deschout, V. Caveliers, B. Descamps, K. Braeckmans, and C. Vanhove et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier Biomaterials 34 2013 2350 2358
46. B. Naeye, H. Deschout, M. Roding, M. Rudemo, J. Delanghe, and K. Devreese et al. Hemocompatibility of siRNA loaded dextran nanogels Biomaterials 32 2011 9120 9127
47. M. Johnsson, and K. Edwards Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids Biophys J 85 2003 3839 3847
48. B.S. Zolnik, A. Gonzalez-Fernandez, N. Sadrieh, and M.A. Dobrovolskaia Minireview: nanoparticles and the immune system Endocrinology 151 2010 458 465
49. G.W. Doorley, and C.K. Payne Cellular binding of nanoparticles in the presence of serum proteins Chem Commun 47 2011 466 468
50. A. Gessner, A. Lieske, B.R. Paulke, and R.H. Muller Functional groups on polystyrene model nanoparticles: influence on protein adsorption J Biomed Mater Res A 65A 2003 319 326
51. B. Lucas, K. Remaut, N.N. Sanders, K. Braeckmans, S.C. De Smedt, and J. Demeester Towards a better understanding of the dissociation behavior of liposome-oligonucleotide complexes in the cytosol of cells J Control Release 103 2005 435 450
52. K. Remaut, B. Lucas, K. Braeckmans, N.N. Sanders, J. Demeester, and S.C. De Smedt Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy J Control Release 110 2005 212 226
53. K. Remaut, B. Lucas, K. Braeckmans, N.N. Sanders, J. Demeester, and S.C. De Smedt Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick? Biochemistry - US 45 2006 1755 1764
54. K. Remaut, B. Lucas, K. Raemdonck, K. Braeckmans, J. Demeester, and S.C. De Smedt Can we better understand the intracellular behavior of DNA nanoparticles by fluorescence correlation spectroscopy? J Control Release 121 2007 49 63
55. L.C. Gomes-da-Silva, N.A. Fonseca, V. Moura, M.C.P. de Lima, S. Simoes, and J.N. Moreira Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges Acc Chem Res 45 2012 1163 1171
56. K. Buyens, J. Demeester, S.C. De Smedt, and N.N. Sanders Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes Langmuir 25 2009 4886 4891
57. D.S. Kohane, J.Y. Tse, Y. Yeo, R. Padera, M. Shubina, and R. Langer Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum J Biomed Mater Res A 77A 2006 351 361
58. S. Dadashzadeh, N. Mirahmadi, M.H. Babaei, and A.M. Vali Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge J Control Release 148 2010 177 186
59. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L.S. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm Res-Dordr 24 2007 1691 1701